Context Graves' disease affects 3% of women and 0.5% of men in the general population. The first line treatment of Graves' hyperthyroidism is based on the administration of antithyroid drugs (ATD), propylthiouracil (PTU), methimazole (MMI) and carbimazole. A recent warning from the Italian Drug Agency (Agenzia Italiana del Farmaco AIFA) reported the risk of MMI-induced acute pancreatitis. In addition, AIFA highlighted the possible association of MMI treatment during the first trimester of pregnancy with congenital malformations, thus recommending the use of effective contraceptive methods in women of childbearing age treated with MMI. Methods and results Revision of literature reported less than ten cases of the alleged MMI pancreatitis, allowing the inclusion of MMI in class III drug regarding the relative risk for drug-induced pancreatitis. Data available on the effect of hyperthyroidism per se on the risk of fetal malformations, although scanty, are sufficient to recommend treatment with ATD of the hyperthyroid pregnant woman. Case reports and population studies either suggesting or not suggesting MMI-induced fetal malformations do not allow unquestionable conclusions on this matter. Conclusions This consensus by experts from Italian Endocrine and Gynecologic Scientific Societies has edited recommendations derived form the available data and published guidelines of International Scientific Societies.
Introduction
Graves' disease affects 3% of women and 0.5% of men in the general population [1] . The first-line treatment of Graves' hyperthyroidism is based on the administration of antithyroid drugs (ATD), the most effective ones belonging to the class of thionamides: propylthiouracil (PTU), methimazole (MMI) and carbimazole (which is rapidly converted to methimazole in the liver). Treatment with ATD is commonly long term, aimed at obtaining a stable remission of the disease [1] .
A recent warning from the Italian Drug Agency (Agenzia Italiana del Farmaco AIFA) reported the risk of developing acute pancreatitis during treatment with MMI. In addition, AIFA highlighted the possible association of MMI treatment during pregnancy with congenital malformations, mainly when the drug is administered in the first trimester of pregnancy and at a high dose. Thus, AIFA recommended the use of effective contraceptive methods in women of childbearing age treated with MMI. It also recommended that MMI should be administered during pregnancy only following a rigorous assessment of the risk/benefit ratio for each individual case (www.agenz iafar maco.gov.it).
Because this warning might have an impact on clinical daily practice of endocrinologists treating hyperthyroidism, especially during pregnancy, in our opinion it is worth discussing available data on these topics. This consensus statement, prepared by experts from Italian of Endocrine and Gynecologic Scientific Societies, was aimed at reviewing the management strategies of hyperthyroidism during pregnancy, in accordance with a careful evaluation of the risk/benefit ratio for the mother and the fetus.
Side effects of ATDS
A small proportion (5%) of hyperthyroid patients treated with MMI experience minor sensitivity reactions, including skin rashes, arthralgias, fever, transient leukopenia or lymph node enlargement [2] . Severe adverse reactions, such as agranulocytosis (estimated frequency 0.1-1.2%) [2] and cytolytic or cholestatic hepatitis (estimated frequency 0.1-0.2%) may rarely occur. Acute pancreatitis was also reported as a rare major adverse side effect of MMI treatment [3] [4] [5] [6] [7] [8] [9] . Since the first report in 1999 [3] , only seven cases of MMI-induced acute pancreatitis were recorded in the literature [4] [5] [6] [7] [8] [9] ( Table 1 ). The cause-effect relationship of this adverse event was recently challenged by a population-based, case-control study performed in Taiwan that analyzed the database of the National Health Insurance program [10] . This investigation, which involved thousands of patients, found no significant association between the use of MMI and the occurrence of acute pancreatitis. In any case, because there are less than ten reported cases of alleged MMI pancreatitis, MMI should be considered as class III drug regarding the relative risk for drug-induced pancreatitis (class III less than 10 cases of pancreatitis after MMI exposure; class II between 10 and 20 cases; class I greater than 20 cases with at least one documented case following re-exposure) [11] . Thus, the possibility of acute pancreatitis during MMI treatment should be kept in mind, but patients should be reassured about its unlikelihood.
Similar rare adverse effects have been reported with PTU use with cutaneous allergic reactions, agranulocytosis, vasculitis, and arthralgias/arthritis [12] . Hepatotoxicity from ATD ranges from mild transaminase elevation to hepatic necrosis resulting in death. Severe hepatocellular disease has been described predominantly with PTU [12] . In the USA between 1990 and 2007, between one and three liver transplants from PTU exposure were reported annually [13] .
Hyperthyroidism during pregnancy
Thyrotoxicosis occurs in 1 of 1000-2000 pregnant women, the most frequent cause being Graves' disease (GD); if not treated, it is associated with a significant increased risk of adverse outcomes and maternal-fetal complications [14, 15] . Preterm labor, fetal loss, low birth weight, hydrops, pregnancy-induced hypertension, maternal congestive heart failure, and major and minor congenital malformations in the offspring were reported [14] . Seizures and neurobehavioral disorders occurring later in life might also be related to fetal exposure to excess maternal thyroid hormones [16] .
Treatment of hyperthyroidism during pregnancy and in the preconceptional period poses significant problems regarding indications for treatment, therapeutic options and use of ATDs. ATDs cross the placenta and may produce fetal-neonatal hypothyroidism and teratogenic effects in the embryo [17, 18] . The first condition results from maternal overtreatment with inappropriately high doses of ATDs [18] . MMI and PTU have similar kinetics of placental crossing [19] , thus making the risk of inducing fetal and neonatal hypothyroidism similar to the two drugs [20] . Thus, the lowest possible dose of ATDs should be used in pregnancy, the goal of treatment being to maintain the maternal serum concentration of free thyroxine (FT4) at the upper limit of the normal range. Graves' disease may spontaneously improve during pregnancy. Accordingly, the dose of ATDs should be tailored and tapered during gestation, based on frequent assessments of maternal thyroid function.
Regarding the teratogenic risk, most experts and guidelines recommend that PTU should be the drug of choice during the first trimester of pregnancy. This is because a so-called "methimazole embryopathy" was described in sporadic cases of neonates born to hyperthyroid mothers being treated with MMI during early pregnancy . PTU also was blamed for teratogenic effects, although the reported malformations appear to be milder than those involved in the so-called "methimazole embryopathy". These topics will be discussed in detail in the following paragraphs. 
Maternal hyperthyroidism as a cause of teratogenic effects
The causal relationship between maternal hyperthyroidism and the risk of congenital abnormalities is still an unsolved matter. In a pivotal paper including 643 Graves' mother-neonate pairs, the authors analyzed hyperthyroid women, either treated or untreated with MMI, and euthyroid women, either treated or untreated to compare the influence of maternal hyperthyroidism vs MMI use during the first trimester of pregnancy on the incidence of congenital malformations [15] . This was higher in hyperthyroid women, while no significant increase was found in euthyroid mothers, independently of treatment with MMI [15] . The results of this study indicated that hyperthyroidism per se, rather than MMI, is responsible for the increased risk of fetal malformations. Similar conclusions were drawn by a multicenter case-control study by Barbero et al. [44] , who analyzed the frequency of maternal exposure to MMI during pregnancy in children with choanal atresia as compared with a randomly selected control group. The study suggested that prenatal exposure to maternal hyperthyroidism and its treatment with MMI were associated with choanal atresia, but, also in this series, maternal disease, rather than its treatment with MMI, was likely responsible for the adverse event. Other studies found no relationship between thyrotoxicosis and congenital malformations in the offspring. Yoshihara et al. [45] reviewing 6744 pregnant women with Graves' concluded that maternal hyperthyroidism had little effect on the rate of congenital malformations in live-born neonates.
Another retrospective investigation reported that untreated hyperthyroidism in the first trimester of pregnancy did not cause an increase in the rate of congenital abnormalities [46] . Recently [47] , the role of abnormal maternal thyroid function in birth cohorts was analyzed and maternal blood samples from early pregnancy were collected. The data of this report showed that the frequency of maternal thyroid dysfunction in early pregnancy was similar in the random cohort and in cases of birth defect [47] , and hyperthyroidism per se was not associated with birth defects. However, the assessment was based on a single measurement of TSH and Ft4 in a blood sample from early pregnancy and repeated testing would have been preferable [47] .
ATDs as a cause of teratogenic effects
In 1972, Milham and Elledge first reported an increased incidence of scalp defects in neonates born to hyperthyroid mothers treated with MMI during pregnancy [22] . Since then, 30 cases of isolated scalp defects were described in children born to mothers treated with MMI during pregnancy [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Later studies reported the association of scalp defects with other congenital malformations, such as imperforate anus, choanal and esophageal atresia, hypoplastic nipple, facial abnormalities and psychological delay [21] . To describe this complex clinical picture, the term "methimazole embryopathy" was minted, for which specific diagnostic criteria were also proposed [21] . Nine case reports of PTU-associated defects were also reported, but even when PTU had been used in the first trimester of pregnancy there was no consistent pattern in the reported defects [48] . In experimental mouse and rat models, no significant microscopic abnormality or gross malformation was observed after long-term treatment with high doses of PTU or MMI during pregnancy [49] .
Epidemiological studies favoring a teratogenic effect of ATD
The above-mentioned case reports, albeit important to highlight possible adverse effects, suffer from the weakness of anecdotal evidence [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Furthermore, different patterns of abnormalities have been reported in patients treated with MMI or PTU, making their teratogenic effect questionable. Epidemiological studies may be more helpful clarifying this issue. However, available population studies are heterogenous because some are prospective, others are retrospective, and some exploit information derived from congenital malformation registers. In many of these studies, relevant clinical information is not available (e.g., thyroid status of the mother, daily dose of ATD, or exact exposure window to ATD during pregnancy) ( Table 2 ). In one of the first population studies, the possible teratogenic effect of MMI was suggested by the observation of an increased incidence of aplasia cutis in a Spanish region where MMI had been illegally used as a fattening agent in animal food [32] . In a prospective cohort study conducted by Di Giannantonio et al. [42] , 241 women exposed to MMI during pregnancy were compared with 1089 pregnant controls who did not receive teratogenic drugs. The general rate (6.3%) of major congenital abnormalities in the MMI-exposed group was not higher than that (6.6%) observed in controls. However, among in utero MMI-exposed infants, two had major malformations described in the MMI embryopathy (1 choanal atresia and 1 esophageal atresia). In these infants, exposure periods were 4-7 weeks and 0-16 weeks of gestation, respectively, but maternal thyroid status was not reported and other teratogenic factors or genetic causes were not excluded. Clementi et al. [50] used a case-affected control analysis with 18,131 cases of malformations reporting first-trimester exposure to medication. A total of 127 subjects were born to mothers with known first-trimester ATD exposure (PTU 47; MMI 80). Among the 52 groups of malformations that were analyzed, situs inversus, dextrocardia, unilateral kidney agenesis/dysgenesis and cardiac outflow tract defects were associated with prenatal exposure to PTU. However, this association was statistically weak and some of the malformations described lacked biological plausibility. Prenatal exposure to MMI was significantly associated with choanal atresia, omphalocele, and situs inversus. Because these data were derived from disease registers, it remains unclear whether the association is driven by maternal disease, the medication, or the combinations of both factors.
A retrospective study indicating that birth defects after MMI exposure in early pregnancy are rather common was performed in Japan. Yoshihara et al. [45] reviewed the hospital records of a large series of women with Graves' disease who had been treated with MMI (n = 1231) or PTU (n = 1399) in the first trimester of pregnancy, or with any ATD before but not during pregnancy (control, n = 1906). Information about congenital defects was obtained from the mothers using a questionnaire, which was administered during their first thyroid consultation after delivery. MMI exposure in early pregnancy (50 cases) was found to be associated with a significantly higher rate (4.1%) of congenital defects (p = 0.002 vs. control). The corresponding figure in PTU-exposed children (12 cases) was 1.9%. Aplasia cutis congenita, omphalocele, and a symptomatic omphalomesenteric duct anomaly were the malformations more frequently observed [45] . The congenital malformation rate in women who did not receive ATDs was 2.1% (40 cases), in keeping with the reported prevalence of congenital malformations in the general Japanese population of live-born neonates.
In 2015, another Japanese retrospective study [51] evaluated 283 women with Graves' disease in whom hyperthyroidism treatment was switched from MMI to potassium iodide (KI) in the first trimester. Also included were 1333 pregnant patients treated with MMI alone. The study reported a significantly higher prevalence of congenital malformations in offspring of MMI-exposed mothers (4.14%) than in the control group of mothers receiving treatment with KI (1.53%). A criticism to this study derives from the observation that children with congenital malformations in the KI group were also exposed to MMI during the early weeks of gestation in which organogenesis takes place.
A nationwide cohort study, performed within the framework of the Korean Health Insurance Review and Assessment Service, included 2,886,970 pregnancies, 12,891 of which were exposed to ATDs [52] . The authors included inpatient admissions and outpatient visits with diagnosis of congenital malformations until the offspring reached the age of 1 year. The prevalence of malformations in exposed offspring was 7.2% compared with 5.9% in offspring of women who did not receive ATD during pregnancy [52] . Compared with pregnancies without ATD prescriptions, the absolute increases in the prevalence of congenital malformations per 1000 live births were: 8.8 cases for PTU alone, 17 cases for MMI alone, and 16.5 cases for PTU/MMI. This is also the only study that reports a dose effect of MMI, the risk of congenital malformations being higher in mothers receiving a cumulative dose of MMI greater than 495 mg as compared with those receiving lower doses in the first trimester of pregnancy [52] .
Two other publications are derived from analysis of registers. By exploiting the Swedish Medical Birth register, 42 women treated with MMI and 50 women treated with PTU during the first trimester of pregnancy were identified [43] . Four cases of infants with esophageal atresia and omphalocele or choanal atresia were found. Three of the four correspondent mothers had taken MMI during the first trimester of pregnancy, while in the fourth the mother had untreated hyperthyroidism. No cases of severe congenital malformations related to PTU administration were reported. However, this study did not provide information on the thyroid status of the mother. The Danish National Register included 817,093 live-born infants, 1820 of whom were exposed to ATDs [53] . Exposure to ATDs during the first trimester was identified by combining data from the Danish Civil Registration System, the Medical Birth Register (identification of the mothers and the first 10 weeks of their pregnancy), and the National Prescription Register (time and type of ATD prescription). The prevalence of birth defects was significantly higher in children exposed to any ATD. In the group of mothers not exposed to ATDs, 5.4% of children had a congenital defect diagnosed before 2 years of age. This prevalence was not different from that observed in the offsprings of the 3543 control mothers who had received ATDs outside pregnancy. On the other hand, 9.1% of in utero MMI/carbimazole-exposed (p < 0.001 vs. control) and 8.0% of PTU-exposed (p = 0.017 vs. control) children had congenital defects [53] . Both MMI/ carbimazole and PTU were associated with urinary system malformations. In particular, 1.6% of the MMI-exposed children had choanal atresia, omphalocele, esophageal atresia, omphalomesenteric duct anomalies, and aplasia cutis. Other types of birth defects were skin defects, digestive system abnormalities, and eye, urinary, respiratory, and cardiovascular defects, mainly ventricular septal defects [53] . MMI/ carbimazole-associated defects fell into 7/13 birth defects subgroups listed in ICD-10, with the highest relative risk for various types of abdominal wall defects. In PTU-exposed infants, congenital malformations of the face and neck region were found that, although being less severe, required surgical correction in 9 of 14 affected children [53] . The most common PTU-associated defect was a pre-auricular sinus or cyst with fistula, a birth defect that is considered minor and often not registered. In this study, the outcomes of birth defects were registered in the hospital before the child was 2 years old. A main reason for the higher prevalence of birth defects in the Danish cohort compared with the Japanese study is that the Danish children were older (2 years) at the time of evaluation for birth defects than the Japanese children who were evaluated as newborns.
In a recent manuscript, an extension of this cohort analyzing 1,243,253 neonates born in Denmark from 1997 to 2016 from a nationwide register-based cohort, 8830 children form the Danish National Birth Cohort, 1997 to 2003, and 14,483 children from the North Denmark region pregnancy cohort, 2011 to 2015, was reported. In this study a higher frequency of birth defect due to methimazole (9.6%) was reported that was statistically significant with respect to controls (6.7%), while a nonsignificant increase in birth defects due to PTU use (8.3%) was observed [47] . In this study information on birth defects in the child was assessed from inpatient and outpatient hospital diagnoses in the Danish National Hospital Register: all diagnoses of birth defects were performed when children were 2 years old [47] .
From these data, it appears that the teratogenic risk of medical treatment of hyperthyroidism with ATDs during pregnancy remains unclear. Studies performed are not homogenous; some authors retrospectively studied clinical records of mothers and offsprings, while other retrospective epidemiological studies analyzed national and international registers of malformations. Also, the time of evaluation of congenital malformations in children is crucial. Birth defects are by definition present at birth, but the defects may not be detected clinically at birth and less severe malformations may be diagnosed at a later age. In fact, many PTUassociated defects would probably not have been detected in some studies, because the children were investigated at a vey young age. Also, other studies did not report the age of children at evaluation. A pertinent question is whether the abnormalities observed in the children might be caused or influenced by maternal hyperthyroidism despite ATDs therapy. The study of Yoshihara [45] and recently of Andersen [47] included data on maternal thyroid function in early pregnancy and found no association between hyperthyroidism and birth defects. However all together, the data available suggest that birth defects may be associated with the use of ATDs in early pregnancy, but are rare. Another important point is the timing of shift from MMI to PTU in pre-pregnancy or early pregnancy [54] as the use of prescription database challenges the methodology. In the study from Korea [52] 2079 pregnant women shifted from MMI to PTU during pre-pregnancy or in early pregnancy. The risk of birth defect was similar in this group compared to those treated with MMI alone. However, the exact timing of shift in therapy in relation to pregnancy start was uncertain. In the Danish study [53] only women who shifted from MMI to PTU after pregnancy start determined the type of ATD exposure in early pregnancy.
Epidemiological studies not favoring the teratogenic effect of ATD
Other studies do not support a role of ATD as teratogenic (Table 3 ). In 1984 a study by Momotani et al. showed that incidence of major malformations was higher in hyperthyroid women (either on or off treatment), while no significant difference was demonstrated between euthyroid MMI-treated and euthyroid non-treated mothers [15] . In this study the overall frequency of malformed infants born to hyperthyroid mothers was 3%, whereas the corresponding rate of malformed infants born to euthyroid mothers was 0.2%. The overall prevalence rates for malformed infants in MMI-treated and in non-treated mothers were 0.8% and 1%, respectively.
A first prospective, controlled cohort study, including 115 PTU-exposed pregnancies and 1141 controls, was performed by Rosenfield et al. [55] . No congenital malformation was reported in pregnant women treated with PTU.
In 2011, the Taiwan's National Health Registry study [56] failed to show an increased prevalence of congenital abnormalities in children born to hyperthyroid mothers treated with either PTU or MMI during gestation. Pregnancy exposure to ATDs was defined as the use of these drugs by the mother for more than 30 days, irrespective of the gestational week. There were 630 PTU-treated and 73 MMI-treated mothers. Congenital abnormalities were found in 0.65% of a control group, which included 14,150 non-exposed neonates born to age-matched mothers. The correspondent figure in the 630 in utero PTU-exposed children was 0.79%. None of the 73 in utero MMI-exposed children had any abnormality. Because of the small number of MMI-exposed cases, the study was underpowered to detect potential teratogenic effects of the drug.
A fourth negative cohort study was a large and detailed US-based retrospective claims database analysis performed using data from 2005 to 2009 by Korelitz et al. [57] . Prescriptions for MMI or PTU filled within 6 months before or during pregnancy were used to define exposure, and the outcome was an ICD-9 code of congenital abnormality diagnosed within 12 months after birth. Among the 108 in utero exposed to MMI children, 6 (5.5%) had birth defects, which was similar to the observed prevalence (5.9%) in the 634,858 control children born to mothers who did not suffer from hyperthyroidism. There were 66 birth defects (7.2%) among the 915 PTU-exposed children, which was not statistically different from controls. In this study, the number of MMI-exposed cases was rather low. Considering PTU, the number of exposed cases was large. However, the study by Korelitz et al. did not report data on pre-auricular sinus or cyst with fistula, the most common defect observed after PTU exposure in the Danish survey [53] . Similar to the Danish study, in the study by Korelitz et al. [57] urinary tract defects were more frequently observed after PTU exposure (7.65/1000 cases vs. 4.38/1000 controls), although a statistically significant difference was not reached [57] . Even though this was a large study, the number of MMI-exposed cases was rather low and, likely, many PTU-associated defects were not recorded in the database.
A fifth negative study originated from a US health database, the central electronic databases of Kaiser Permanente of Northern California [58] . In this study, exposure was defined as ATD therapy at some point during pregnancy, and the presence of birth defects was evaluated by searching for a relevant ICD-9 diagnosis (apparently excluding congenital skin abnormalities and unspecified congenital abnormalities). The age at evaluation was not specified, but appeared to be shortly after birth. Exposure time in relation to the week of gestation was not accurately reported. A total of 18 (3%) defects were detected among the 586 ATD-exposed children, whereas 52/1117 (4.6%) children born to mothers diagnosed with hyperthyroidism, but with no ATD exposure in pregnancy had birth defects. The majority of the pregnant women treated had received PTU. Overall, differences between groups were not statistically significant. The ability of this study to detect MMI-associated defects was very low, and as discussed above many PTU-associated defects were probably not detected in this study because children were investigated at a very young age. A sixth negative study is an Italian multicenter survey, which included eight endocrine units [17] . There were 124 MMI-exposed, 52 PTU-exposed, and 203 control children (born to mothers suffering from other thyroid diseases not associated with hyperthyroidism). Outcomes were retrospectively investigated based on medical records. In this manuscript, the clinical and biochemical data of mothers and children were available. Thyroid function tests were monitored monthly and doses of ATD were known. Thus, maternal thyroid function during the whole period of pregnancy was known. No association was observed between ATD use and congenital defects identified during the first few days after birth; however, no other congenital defects were reported in children in later years.
A seventh epidemiological, registry-based, retrospective study [59] was performed in Sweden and conceptualized to extend the burden of evidence, particularly the findings in the Danish study on birth defects. The study was nationwide, and definitions of exposure and outcome similar to the Danish study were used. No overall increased incidence of birth defects was observed in children born to mothers treated with MMI or PTU in early pregnancy compared with non-exposed pregnancies. The overall prevalence of birth defects was 8% in non-exposed children, 6.8% in the MMI-exposed and 6.4% in the PTU-exposed ones. When the type of congenital abnormality was analyzed, PTU and MMI were associated with the same types of birth defects previously described in the Danish study, including ear and urinary tract malformations after PTU exposure and heart septal defects after MMI exposure. Severe malformations, such as those included in the MMI embryopathy, were rarely observed in this study. A methodological limitation of this study was the low number of MMI-exposed pregnancies.
Conclusions
Regarding the recent warning from the Italian Drug Agency that reported the risk of developing acute pancreatitis during treatment with MMI, we advise that, due to the paucity of available data, the possibility of acute pancreatitis during MMI treatment should be kept in mind, but would not prevent the physician in prescribing the drug and patients should be reassured about its unlikelihood.
Management and treatment of pregnant women with hyperthyroidism and the related counseling are important issues, because optimal fetal and maternal outcomes depend on controlling the mother's hyperthyroidism and ATD administration at proper dose. Serum thyroid hormone levels should be maintained in the upper part of normal range to prevent fetal hypothyroidism, due to a higher sensitivity of the fetal thyroid to the action of ATDs. As highlighted throughout this review, evidence for these teratogenic effects and in particular for their prevalence is still controversial. However, ATD exposure in the first trimester of pregnancy appears to be weakly, but significantly associated with congenital abnormalities, the reported teratogenic effects being more severe with MMI and carbimazole than with PTU. All considered, it is reasonable to take into account current recommendations of the American Thyroid Association Guidelines for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum [60] and the European Thyroid Association Guidelines for the Management of Graves' Hyperthyroidism" in women with Graves' disease planning pregnancy [61] . Accordingly, the Associazione Italiana della Tiroide (AIT), Società Italiana di Endocrinologia (SIE) and Società Italiana di Ginecologia ed Ostetricia (SIGO) advise that:
1. Hyperthyroid women with Graves' disease should be offered preconception counseling on the importance of planning their pregnancy ahead, which should be postponed if hyperthyroidism is inadequately controlled. Switching to PTU before conception is recommended. 2. In MMI-treated women with unplanned pregnancy, therapeutic abortion is not warranted. In these women ,switching to PTU as soon as possible is recommended; in some countries (like Italy) where PTU is available only by a request to AIFA, before getting PTU, MMI should not be discontinued. 3. Prior to initiating PTU treatment, baseline liver function tests should be obtained; 4. In women diagnosed with symptomatic, moderate to severe hyperthyroidism during the first trimester of pregnancy, treatment with PTU should be initiated. 5. In pregnant women taking PTU during the first trimester, it is recommended to switch to MMI in the second trimester (16 weeks). 6. Women diagnosed with symptomatic, moderate to severe hyperthyroidism after the first trimester should be treated with MMI. 7. In a pregnant woman with Graves' disease who is euthyroid on a low dose of MMI or PTU, an attempt to discontinue ATDs can be done. Maternal thyroid function testing should be performed thereafter; the goal is to maintain serum thyroid hormones at the upper part of normal range. 8. In pregnant women at high risk of relapsing hyperthyroidism, continued medical treatment is advised. 9. Any pregnant woman affected by Graves' diseases should be referred to a third level center because of the higher obstetric risks related to maternal hyperthyroidism. A multidisciplinary approach is needed to reduce fetal-maternal risks. 10. Patients should be adequately informed on the prevalence and heterogeneity of congenital abnormalities attributed to the use of ATD in pregnancy. An appropriate counseling can avoid misinformation and unnecessary pregnancy terminations. Contraceptive methods in women of childbearing age treated with MMI are not necessary.
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